Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...

Co., Inc. (NYSE:MRK), recently acquired 15,000 shares of the company's common stock. The transaction, which took place on ...

RBC Capital Markets analyst Bish Koziol made eight changes to his quantitatively driven top 40 list of stock picks. Maple ...

Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...

Here are seven attractively valued dividend stocks investors can bet on for the long term, according to Bank of America ...

DJIA stocks to watch today. Market trends show gains in retail, tech, and energy. Get insights on Walmart, Apple, Amazon, and more!

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.

Wall Street rebounds as tech stocks surge, with the S&P 500 up 0.5% amid easing trade tensions and strong corporate earnings.

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.